Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 19095646 
Neppl RL, et al. (2009) Thromboxane A2-induced bi-directional regulation of cerebral arterial tone. J Biol Chem 284, 6348-60 19095646
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S20-p - MRLC2 (rat)
Orthologous residues
MRLC2 (human): S20‑p, MRLC2 (mouse): S20‑p, MRLC2 (rat): S20‑p, MRLC2 (cow): S20‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  cerebral artery
 Cellular systems studied:  tissue
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
U46619 increase
cGMP analog U46619 inhibit treatment-induced increase
cGMP analog decrease

S696-p - MYPT1 (rat)
Orthologous residues
MYPT1 (human): S695‑p, MYPT1 iso4 (human): S636‑p, MYPT1 (mouse): S693‑p, MYPT1 (rat): S696‑p, MYPT1 (pig): S695‑p, MYPT1 (chicken): S694‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  cerebral artery
 Cellular systems studied:  tissue
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
U46619 increase
cGMP analog U46619 no effect upon treatment-induced increase
cGMP analog, Triton X-100 increase
L-NAME decrease
L-NAME U46619 inhibit treatment-induced increase

T697-p - MYPT1 (rat)
Orthologous residues
MYPT1 (human): T696‑p, MYPT1 iso4 (human): T637‑p, MYPT1 (mouse): T694‑p, MYPT1 (rat): T697‑p, MYPT1 (pig): T696‑p, MYPT1 (chicken): T695‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  cerebral artery
 Cellular systems studied:  tissue
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
U46619 increase
cGMP analog U46619 no effect upon treatment-induced increase
cGMP analog no change compared to control
L-NAME increase
L-NAME U46619 augment treatment-induced increase
Downstream Regulation
 Effect of modification (function):  activity, inhibited

T855-p - MYPT1 (rat)
Orthologous residues
MYPT1 (human): T853‑p, MYPT1 iso4 (human): T794‑p, MYPT1 (mouse): T852‑p, MYPT1 (rat): T855‑p, MYPT1 (pig): , MYPT1 (chicken): T850‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  cerebral artery
 Cellular systems studied:  tissue
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
U46619 increase
cGMP analog U46619 no effect upon treatment-induced increase
cGMP analog no change compared to control
L-NAME increase
L-NAME U46619 augment treatment-induced increase
Downstream Regulation
 Effect of modification (function):  activity, inhibited, intracellular localization

T38-p - PPP1R14A (rat)
Orthologous residues
PPP1R14A (human): T38‑p, PPP1R14A iso2 (human): T38‑p, PPP1R14A (mouse): T38‑p, PPP1R14A (rat): T38‑p, PPP1R14A (pig): T38‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  cerebral artery
 Cellular systems studied:  tissue
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
U46619 no change compared to control
cGMP analog U46619 no change compared to control

S154-p - VASP (rat)
Orthologous residues
VASP (human): S157‑p, VASP (mouse): S153‑p, VASP (rat): S154‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  cerebral artery
 Cellular systems studied:  tissue
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
L-NAME decrease

S236-p - VASP (rat)
Orthologous residues
VASP (human): S239‑p, VASP (mouse): S235‑p, VASP (rat): S236‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  cerebral artery
 Cellular systems studied:  tissue
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
cGMP analog increase
L-NAME decrease


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.